Cargando…

127. Living on the Edge: The Impact of MIC Distributions on Empiric Antibiotic Selection

BACKGROUND: Due to variability in the precision of an MIC, concern may exist in optimizing PK/PD using standard doses when the MIC is at the susceptibility breakpoint (SBP). This is notable when treating infections in critically ill patients. Evaluating MIC distributions among commonly used antibiot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bauer, Karri A, Hidayat, Levita K, Klinker, Kenneth, Motyl, Mary, Andrew DeRyke, C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643761/ http://dx.doi.org/10.1093/ofid/ofab466.329

Ejemplares similares

103. Empiric Antibiotic Susceptibility Using a Traditional vs. Syndromic Antibiogram-Implications for Antimicrobial Stewardship Programs
por: Klinker, Kenneth, et al.
Publicado: (2020)

151. Simplifying Empiric Antimicrobial Therapy Selection for Lower Respiratory Tract Infections in Intensive Care Unit Patients: Using Resistance Frequency to Guide Decision Making
por: Klinker, Kenneth, et al.
Publicado: (2021)

Antimicrobial stewardship and antibiograms: importance of moving beyond traditional antibiograms
por: Klinker, Kenneth P., et al.
Publicado: (2021)

Use of Novel Antibiograms to Determine the Need for Earlier Susceptibility Testing and Administration for New β-Lactam/β-Lactamase Inhibitors in the United States
por: Klinker, Kenneth P., et al.
Publicado: (2022)

1450. Frequency of Carbapenem-resistant Pseudomonas aeruginosa Among Respiratory Pathogens Impacts First-Line Beta-Lactam Susceptibility: Potential Role for Ceftolozane/Tazobactam (C/T) and/or Imipenem/Relebactam (I/R)
por: Klinker, Kenneth, et al.
Publicado: (2020)

1274. Activity of Ceftolozane/Tazobactam, Imipenem/Relebactam, and Comparators Against Pseudomonas aeruginosa Isolates from Patients with Bloodstream and Other Infection Types—SMART United States/Canada 2018-2019
por: Lob, Sibylle, et al.
Publicado: (2021)

1273. Activity of Ceftolozane/Tazobactam and Comparators Against Enterobacterales and P. aeruginosa Isolates from Pediatric Patients—SMART United States 2017-2019
por: Lob, Sibylle, et al.
Publicado: (2021)

1670. Activity of Ceftolozane/Tazobactam and Comparators Against Clinical MDR and DTR Pseudomonas aeruginosa isolates – SMART United States 2018-2020
por: Lob, Sibylle, et al.
Publicado: (2022)

1671. Activity of Imipenem/Relebactam and Comparators Against Gram-Negative MDR and DTR Pathogens from Patients with Respiratory and Bloodstream Infections – SMART United States 2018-2020
por: Lob, Sibylle, et al.
Publicado: (2022)

1603. Comparison of Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Meropenem/Vaborbactam Activity Against P. aeruginosa: A Multicenter Evaluation
por: Moise, Pamela, et al.
Publicado: (2020)

Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018–2020
por: Hilbert, David W., et al.
Publicado: (2023)

2154. Cross-resistance of Ceftolozane-Tazobactam and Imipenem-Relebactam Against Clinical P. aeruginosa Isolates from Bloodstream and Respiratory Tract Infections– SMART United States 2019-2021
por: Lob, Sibylle, et al.
Publicado: (2023)

2152. Activity of Imipenem/Relebactam Against Carbapenem-Resistant Non-Morganellaceae Enterobacterales (NME) in the United States – SMART 2019-2021
por: Lob, Sibylle, et al.
Publicado: (2023)

1220. Is MIC all that matters? MIC Distributions of Ceftazidime and Cefepime in Ceftriaxone-Resistant E. coli and Klebsiella spp
por: Heil, Emily, et al.
Publicado: (2021)

1674. Trends in Antimicrobial Susceptibility to Ceftolozane/Tazobactam and Comparators of Pseudomonas aeruginosa from Patients with Respiratory Tract Infections in Five Latin American Countries – SMART 2017-2020
por: Lob, Sibylle, et al.
Publicado: (2022)

2155. Low prevalence of OXA-48-like carbapenemases and susceptibility to imipenem/relebactam among carbapenem-resistant non-Morganellaceae Enterobacterales isolates from Latin America – SMART 2018-2021
por: Lob, Sibylle, et al.
Publicado: (2023)

163. MIC Shifts in Response to Increased Antibiotic Utilization During COVID-19 Pandemic
por: Byrd, Jonathan, et al.
Publicado: (2021)

127. A Retrospective Review of Antibiotic Appropriateness for Urinary Tract Infections in Ambulatory Patients
por: Donohoe, Kendall, et al.
Publicado: (2020)

1080. Relebactam Increases Imipenem Activity Against Imipenem-Nonsusceptible and -Susceptible Pseudomonas aeruginosa and Enterobacterales: Assessment of Isolates from RESTORE-IMI 2
por: Hilbert, David W, et al.
Publicado: (2021)

Association of SARS-CoV-2 status and antibiotic-resistant bacteria with inadequate empiric therapy in hospitalized patients: a US multicenter cohort evaluation (July 2019 - October 2021)
por: Bauer, Karri A., et al.
Publicado: (2023)

Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards—SMART United States 2017–2019
por: Lob, Sibylle H, et al.
Publicado: (2021)

In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020
por: Karlowsky, James A., et al.
Publicado: (2023)

Susceptibility profile and β-lactamase content of global Pseudomonas aeruginosa isolates resistant to ceftolozane/tazobactam and/or imipenem/relebactam—SMART 2016–21
por: Karlowsky, James A, et al.
Publicado: (2023)

The impact of initial antibiotic therapy (linezolid, vancomycin, daptomycin) on hospital length of stay for complicated skin and soft tissue infections
por: Szczypinska, Ewa, et al.
Publicado: (2013)

In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with lower respiratory tract infections in Western Europe: SMART 2018–20
por: Karlowsky, James A, et al.
Publicado: (2023)

WGS to predict antibiotic MICs for Neisseria gonorrhoeae
por: Eyre, David W., et al.
Publicado: (2017)

Collective assessment of antimicrobial susceptibility among the most common Gram-negative respiratory pathogens driving therapy in the ICU
por: Moise, Pamela A, et al.
Publicado: (2021)

Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in central and northern Europe (Belgium, Norway, Sweden, Switzerland)—SMART 2017–21
por: Karlowsky, James A, et al.
Publicado: (2023)

325. Empiric Antibiotics for COVID-19 and the Utility of Procalcitonin
por: Desens, Adrienne D, et al.
Publicado: (2021)

1227. Plazomicin Susceptibility Testing using ETEST(®) MIC for Enterobacterales
por: Ying, Yun, et al.
Publicado: (2020)

1460. Imipenem/Cilastatin (IMI)/Relebactam (REL) in Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia (HABP/VABP): Subgroup Analyses of Critically Ill Patients in the RESTORE-IMI 2 Trial
por: Chen, Luke F, et al.
Publicado: (2020)

Impact of empirical antibiotic therapy and mortality in the elderly with septic shock
por: Oliveira, GMMO, et al.
Publicado: (2005)

Sepsis: impact of timely and appropriate empirical antibiotic therapy on mortality
por: Serpa-Pinto, L, et al.
Publicado: (2014)

Vancomycin MIC Distribution among Methicillin-Resistant Staphylococcus Aureus. Is Reduced Vancomycin Susceptibility Related To MIC Creep?
por: Othman, Hala B., et al.
Publicado: (2018)

MIC1 and MIC3: partners in invasion
por: Van Epps, Heather L.
Publicado: (2005)

1230. Clinical and Microbiologic Outcomes by Causative Pathogen in Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Treated with Imipenem/Cilastatin (IMI)/Relebactam (REL) Versus Piperacillin/Tazobactam (PIP/TAZ)
por: Losada, Maria C, et al.
Publicado: (2020)

De-escalation of empiric antibiotic therapy in sepsis - an indian observational study
por: Jakkinaboina, S, et al.
Publicado: (2015)

Evaluation of adequacy in empirical antibiotic therapy in a general intensive care unit
por: Friedman, G, et al.
Publicado: (2005)

142. Frequency of Short-course Empiric Antibiotic Use as an Antimicrobial Stewardship Metric
por: McGregor, Jessina C, et al.
Publicado: (2020)

1455. Potential Mechanisms of Cefiderocol MIC Increase in Enterobacterales in In Vitro Resistance Acquisition Studies
por: Yamano, Yoshinori, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jtp6ha0nrp7huiuiroqo95de3t